NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 89 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 2.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $167,000 | +26.5% | 12,757 | +23.6% | 0.00% | – |
| Q2 2022 | $132,000 | -48.6% | 10,325 | +14.8% | 0.00% | – |
| Q1 2021 | $257,000 | -24.4% | 8,996 | -20.4% | 0.00% | – |
| Q4 2020 | $340,000 | +37.1% | 11,302 | -26.4% | 0.00% | – |
| Q3 2020 | $248,000 | +17.0% | 15,347 | +42.7% | 0.00% | – |
| Q2 2020 | $212,000 | +57.0% | 10,756 | 0.0% | 0.00% | – |
| Q1 2020 | $135,000 | -28.9% | 10,756 | +3.7% | 0.00% | – |
| Q4 2019 | $190,000 | -47.7% | 10,371 | -60.5% | 0.00% | -100.0% |
| Q3 2019 | $363,000 | – | 26,236 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 15,396,116 | $303,611,000 | 42.97% |
| Ponoi II Management, LLC | 1,298,908 | $25,614,000 | 20.76% |
| Ponoi Management, LLC | 1,298,908 | $25,614,000 | 14.23% |
| Euclidean Capital LLC | 1,493,349 | $29,449,000 | 9.56% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $74,279,000 | 6.80% |
| Aquilo Capital Management, LLC | 1,194,237 | $23,550,000 | 6.12% |
| Greenspring Associates, LLC | 1,573,357 | $31,027,000 | 2.10% |
| Octagon Capital Advisors LP | 200,000 | $3,944,000 | 0.82% |
| Redmile Group, LLC | 2,792,448 | $55,067,000 | 0.82% |
| BVF INC/IL | 955,000 | $18,833,000 | 0.71% |